1 unchanged sentence
(c) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements
−Removed: On February 3, 2026 , Hans van Houte , Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 173,860 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Mr.
−Removed: van Houte and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Mr.
−Removed: The shares will be sold at the times and prices specified in the van Houte Plan.
−Removed: The van Houte Plan expires on April 30, 2027 , or upon the earlier completion of all authorized transactions thereunder.
−Removed: On February 27, 2026 , Gwenn M.
−Removed: Hansen , Chief Scientific Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Hansen Plan), providing for the potential sale of up to 52,460 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Dr.
−Removed: Hansen and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Dr.
−Removed: The shares will be sold at the times and prices specified in the Hansen Plan.
−Removed: The Hansen Plan expires on May 31, 2027 , or upon the earlier completion of all authorized transactions thereunder.
−Removed: No other director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended February 28, 2026.
+Added: No director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended May 31, 2026.
Incorporated by Reference Filed or Furnished Herewith
4 unchanged sentences
8-K 001-39398 10.1 March 6, 2026
+Added: 10.2*† Seventh Amendment to Collaboration and License Agreement, dated April 8, 2026, by and between the Registrant and Genzyme Corporation
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
9 unchanged sentences
104 Cover Page Interactive Data File (formatted as Inline XBRL and included in exhibit 101) X
−Removed: * The certifications furnished in Exhibits 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.
+Added: * Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K.
+Added: † Registrant has omitted certain schedules pursuant to Item 601(a)(5) of Regulation S-K.
+Added: ‡ The certifications furnished in Exhibits 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NURIX THERAPEUTICS, INC.
−Removed: April 8, 2026
/s/ A RTHUR T.
2 unchanged sentences
(Principal Executive Officer)
−Removed: April 8, 2026
/s/ H ANS VAN H OUTE
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.